Dynamic Precision Library News Today

SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its

- Data for masked anti-CTLA-4 SAFEbody® ADG126 highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable colorectal cancer with higher, more...

SAN DIEGO and SUZHOU, China, Feb. 27, 2024 -- Adagene Inc. , a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the...

- Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks in combination with pembrolizumab anticipated in 2024 at a medical conference - - Initiated evaluation of...

Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its ...

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...

Adagene announced a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime...

- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – - Integrated...

Adagene announced its poster presentation at the SITC 38th Annual Meeting taking place November 1-5, 2023 in San Diego